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impairment: 36.3%±24.8%. The most prevalent symptoms at baseline were abdominal 
pain (85.3%), constipation (7.5%) and bloating (76.5%). Mean IBS-QoL was 61.8±18.2 
(scale: 0-100 [worst-best]). Mean EQ-5D was 58.4±20.2 (scale: 0-100 [worst-best]) and 
85.3% and 50.9% of patients reported moderate-to-severe problems in pain/discom-
fort and anxiety/depression, respectively. Over the year, 78.4% patients consulted 
a primary care physician and 69.6% a gastroenterologist, 18.6% patients required 
emergency department visits/hospitalisation and 66.7% had a diagnostic test. 54.9% 
patients took prescription drugs for their IBS-C and 69.6% took non-prescription 
drugs. Mean (95%CI) annual direct costs per patient for Germany’s national health-
care system: € 1,423 (621-2601); cost for the patient: € 539 (313-841); indirect cost: € 2,619 
(1400-4131). The total annual cost: € 4,581 (2935-6569). ConClusions: Moderate-to-
severe IBS-C symptoms greatly impact German QoL and work productivity. Current 
management practices result in high direct and indirect costs. This results in signifi-
cant cost to both the German national healthcare service and the patient, with the 
latter assuming one quarter of all direct medical costs.
PGI13
Costs of Inflamatory Bowel DIsease (Crohns DIsease anD UlCeratIve 
ColItIs) In serBIa
Kostic M1, Djakovic L2, Sujic R2, Jankovic S3
1Faculty of Medical Sciences,University of Kragujevac, Kragujevac, Serbia and Montenegro, 
2UKUKS, Belgrade, Serbia and Montenegro, 3Faculty of Medical Sciences, University of Kragujevac, 
Kragujevac, Serbia and Montenegro
objeCtives: Ulcerative colitis and Crohn´s disease, have a significant impact 
on health care budget. The aim of this study was to estimate costs of treatment 
and utilization of resources by patients with inflammatory bowel disease (IBD) in 
Serbia. Methods: We performed a population-based, cost of illness study to iden-
tify direct, indirect and out of pocket costs of treatment of patients with IBD from 
societal perspective. Patients with Crohn´s disease (n = 59) and patients with ulcera-
tive colitis (n = 53) completed semi-structured questionnaire with data about utiliza-
tion of heath resources and illness-related expenditures. All costs were calculated 
in Republic of Serbia dinars (RSD), at one-year level. Results: Total direct costs 
per patient-year in group with Crohn´s disease were 1.602,97 Euro (192.614,32 RSD) 
and total indirect costs per patient-year in group with Crohn’s disease were 233,13 
Euro (28.014,00 RSD). Total direct costs per patient-year in group with ulcerative 
colitis were estimated on 1.183,97 Euro (142.267,15 RSD) and total indirect costs per 
patient-year in group with ulcerative colitis were estimated on 178,39 Euro (21.436,00 
RSD). The greatest part od direct costs were incurred by hospitalization (52.350,00 
RSD per patient-year for Crohn’s disease, and 47.895,00 RSD for ulcerative colitis), 
due to prolonged stay in a hospital (31 days per patient-year for Crohn’s disease, 
and 34 days for ulcerative colitis). ConClusions: Costs of IBD in Serbia are lower 
than in developed countries for two reasons: relatively expensive biologic therapy 
is under-utilized, and prices of health services largely used by the IBD patients are 
controlled by state on a very low level.
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objeCtives: The aims of our multicenter study were to quantify direct medical 
costs during interferon (IFN)-based antiviral treatment and per sustained viro-
logical response (SVR) among patients with chronic hepatitis C-virus (HCV) infec-
tion and advanced hepatic fibrosis in the Netherlands, Germany, Switzerland and 
Canada. Methods: Direct medical costs were quantified during IFN-based treat-
ments received by all consecutive patients (N= 455) with chronic HCV infection and 
biopsy-proven bridging fibrosis or cirrhosis (Ishak scores 4-6). The components of 
care from initiation of therapy were quantified by three distinct categories: treat-
ment, safety-monitoring and complications. Total medical costs attributable to each 
cost component were calculated and expressed in 2013 Euros. Sensitivity analyses 
were performed to explore the influence of components of care and the SVR rate 
on medical costs. Results: In total, 672 IFN-based treatments, administered to 455 
patients, were included in the analysis. At time of inclusion, median age was 48 
years (IQR 43–56), 317 (70%) patients were male, and 346 (76%) presented with cir-
rhosis. Platelet counts were available for 432 (95%) patients, of whom 226 (52%) had 
thrombocytopenia. Total mean medical costs per treatment were € 14,559 (95% CI, 
€ 13,323-€ 15,836). Among patients with a normal platelet count and thrombocytopenia, 
mean costs were € 12,419 (95%CI, € 10,974-€ 13,937) and € 14,416 (95%CI, € 12,503-€ 16,598), 
respectively. The costs per SVR were € 26,105 (95%CI, € 23,068-€ 29,296) for patients 
with normal platelet counts and € 50,907 (95%CI, € 44,151-€ 59,612) for patients with 
thrombocytopenia. In patients with severe thrombocytopenia (platelet count below 
100*109/L) the costs per SVR were € 74,961 (95%CI, € 55,463-€ 103,541). The correspond-
ing SVR rates were 48%, 28% and 18%, respectively. Sensitivity analyses confirmed 
the robustness of our results. ConClusions: Real-world medical costs did not differ 
significantly among patients with or without thrombocytopenia. However, the SVR 
rate was lower among patients with severe thrombocytopenia, in whom the medical 
costs per SVR with IFN-based therapy were substantial.
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heterogeneous extensive metabolizer, which had the incremental cost effectiveness 
ratio of ¥57,810 per QALY gained. Probabilistic sensitivity analysis suggests that 
the results are robust with 97% probability that ilaprozole is consider cost effective 
when 3 times China average GDP per capital threshold is used. ConClusions: The 
cost-effectiveness analysis results demonstrated that ilaprazole would be consid-
ered cost-effective compared with omeprazole to treat newly diagnosed duodenal 
ulcer patient in China. When treating the duodenal ulcer patients who are CYP2C19 
subpopulation of heterogeneous extensive metabolizer, ilaprazole is highly cost-
effective, compared with omeprazole.
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objeCtives: Incisional hernias are common following abdominal surgery and place 
a significant burden on patients and healthcare resources. There are two main 
approaches to mesh-based surgical repair of an incisional hernia: open surgery 
and laparoscopy. To date, however, no consensus has been reached as to which 
approach is preferred. The aim of this study was to review the strengths and weak-
nesses of current clinical and economic evidence comparing laparoscopic with open 
repair of incisional hernias. Methods: Studies investigating clinical and economic 
outcomes of laparoscopic and open incisional hernia repair published between 
2003–2014 were identified. Due to the paucity of available data, evidence is supple-
mented using findings from large database studies. Other types of study were con-
sidered for specific outcomes only when no other evidence was available. Results: 
Overall, there is a relatively large body of consistent evidence to conclude that 
laparoscopic repair of incisional hernia is at least equal to open repair in terms of 
mortality, short- to medium-term recurrence, complications, pain and quality of life, 
with a possibly longer operative time. In addition, laparoscopic repair of incisional 
hernia has consistently been shown to be associated with fewer infections and a 
shorter hospital stay than open repair. Although economic data are limited, there 
is consistent evidence from studies that compared the costs for both laparoscopic 
and open repair of incisional/ventral hernia to suggest that the higher operational 
costs associated with laparoscopic repair, which have been attributed, variously, to 
a longer operative time, a need for more expensive mesh or greater supply costs in 
several studies appear to be offset by the shorter hospital stay associated with the 
procedure. ConClusions: There is consistent evidence to suggest that laparo-
scopic repair is associated with lower rates of infection and shorter hospital stays 
(and consequently lower overall costs) than open surgery.
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objeCtives: To perform comparative pharmacoeconomic study of the applica-
tion of IV generation of pancreatin drugs in patients with pancreatic exocrine 
insufficiency on the hospital stage of medical care. Methods: A pharmacoeco-
nomic model of administration of IV generation of pancreatin drugs (creon and 
ermital) in adult patients (100 persons in compared groups) during replacement 
therapy of pancreatic functional insufficiency was developed. Dosage of the drugs 
was at least 100 000 units of lipolytic activity per 24 h. Time horizon was 21 days. 
Measures of clinical efficiency of the applied therapy were the number of patients, 
who would reach clinical response according to „pain relief” and „diarrhea relief” 
parameters. Results: In the modeled conditions, costs of drug therapy per patient 
were within the range of 962.78 — 1,869.56 RUB in the group of creon and 736.12 
— 1,237.20 for ermital, depending on the dose. CER values were: pain relief in the 
range of 1,046.5 — 2,032.13 in creon group, and 836.50 — 1,405.90 in ermital group; 
diarrhea relief was in the range of 927.38 — 1,927.38 in creon group and 783.10 — 
1,316.17 in ermital group. ConClusions: The conducted clinical and economical 
research demonstrated pharmacoeconomic advantages of ermital administration. 
It should be noted that the results of this work were significantly influenced by the 
applied dosages of medications, which were one of the key factors of economical 
substantiation of use of the considered medical technologies.
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objeCtives: To assess the socio-economic burden of moderate-to-severe IBS-C in 
six European countries (France, Germany, Italy, Spain, Sweden and UK). Here we 
present the economic and quality of life (QoL) results from Germany. Methods: 
Observational, retrospective-prospective (6 months each) study of patients diagnosed 
in the last five years with IBS-C (Rome-III criteria) and with moderate-to-severe dis-
ease at inclusion (IBS-Symptom Severity Scale [IBS-SSS] score ≥ 175). The primary 
objective was to determine annual direct and indirect costs. Secondary objectives 
included assessing QoL at baseline: IBS-QoL and EuroQoL-5D (EQ-5D) question-
naires. Work productivity was assessed using the Work Productivity and Activity 
Impairment:IBS-C questionnaire (WPAI:IBS-C). Results: 102 patients were included 
from Germany: mean (±SD) age 47.6±18.1 years, 83.3% female, 43.1% severe (IBS-SSS). 
In the week prior to baseline, mean presenteeism (WPAI:IBS-C) was: 35.6%±28.2% of 
time; absenteeism: 14.7%±28.2%; work productivity loss: 44.1%±32.7%; daily activity 
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objeCtives: Irritable bowel syndrome (IBS) can be diagnosed clinically and man-
aged within primary care, yet around 25% of patients are referred to gastroen-
terology. The objective of this study was to estimate the cost-effectiveness of a 
gastroenterology outpatient appointment for IBS from the perspective of the health 
service payer (UK NHS) over a three year time horizon. Methods: Individual level 
healthcare utilization data were extracted for 2076 IBS patients within the UK 
Clinical Practice Research Dataset with linked Hospital Episode Statistics data who 
first visited a gastroenterologist in 2008 or 2009. Individual costs of total health-
care utilization were calculated for three years before and after gastroenterology 
attendance in 2012 UK£. Quality Adjusted Life Years (QALYs) were modeled from 
utility values reported in a questionnaire study of 69 patients with IBS attending 
a gastroenterology outpatient clinic for the first time. Costs and QALYs before the 
appointment were used to represent costs in the absence of seeing a gastroenter-
ologist. Mean cost per QALY of a gastroenterology appointment compared to no 
referral over three years produced the incremental cost effectiveness ratio (ICER). 
Bootstrapping generated a 95% confidence interval (CI). Net-benefit analysis gen-
erated a Cost Effectiveness Acceptability Curve (CEAC). Scenario and probabilistic 
sensitivity analyses assessed structural and parameter uncertainty. Results: 
The expected QALY gain for a gastroenterology appointment for IBS compared to 
no appointment was 0.14. The expected extra total healthcare costs were £3002. 
The ICER was £21767.08/QALY (95% CI £17078/QALY to £26495/QALY). Likelihood 
of cost-effectiveness at a threshold of £20000/QALY was 25% and 100% at £30000/
QALY. Lower expected QALYs following appointment increases the ICER to £34550/
QALY. ConClusions: Depending on the level of the cost-effectiveness threshold, 
referral to a secondary care gastroenterologist for IBS could be cost-effective for the 
NHS but more robust data on potential QALY gains are needed.
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objeCtives: To evaluate the cost-effectiveness of 10mg ilaprazole once daily vs. 
20 mg omeprazole once daily to treat newly diagnosed duodenal ulcer patients in 
China. Methods: A decision tree model was constructed and the treatment impact 
was projected up to one year. The CYP2C19 polymorphism distribution in the Chinese 
population, the respective cure rates in the CYP2C19 genotype subgroups, the impact 
of duodenal ulcer on utility, and drug related side effects data were obtained from 
literature. The total cost of medications were calculated to estimate treatment costs 
based on current drug retail prices in China. Expert survey was conducted when 
published data were not available to populate the model such as costs of the side 
effects. The main summary measure in this evaluation was incremental cost per 
quality-adjusted life-years (QALY) gained. Probabilistic sensitivity analysis was per-
formed to determine the robustness of the results. Results: Ilaprazole achieved a 
better overall efficacy, because it is less impacted by CYP2C19 genotype subgroups. 
Compared with omeprazole, ilaprazole achieved an incremental cost effectiveness 
ratio of ¥138,941 per QALY gained which is less than the 3 times of China average GDP 
per capital (2014). A subgroup analysis suggests Ilaprazole is most cost-effective in 
the CYP2C19 subpopulation of heterogeneous extensive metabolizer, which had the 
incremental cost effectiveness ratio of ¥60,824 per QALY gained. Probabilistic sensitiv-
ity analysis suggests that the results are robust with 95% probability that ilaprozole 
is consider cost effective when 3 times China average GDP per capital threshold 
is used. ConClusions: The cost-effectiveness analysis results demonstrated that 
ilaprazole would be considered cost-effective compared with omeprazole to treat 
newly diagnosed duodenal ulcer patient in China. When treating the duodenal ulcer 
patients who are CYP2C19 subpopulation of heterogeneous extensive metabolizer, 
ilaprazole is highly cost-effective, compared with omeprazole.
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objeCtives: The aim of the study was to compare the cost-effectiveness of esome-
prazole with other PPIs currently reimbursed in Poland in the acute treatment of 
gastroesophageal reflux disease (GERD). Methods: A decision analysis model 
simulating the treatment of GERD over the course of 8 weeks was developed. The 
duration of treatment is in line with the one recommended by the general guide-
lines. Healing rates were pooled from the existing clinical trials comparing esome-
prazole with other PPIs. All patients were initially treated with PPI at high-dose for 
4 weeks. Subsequently, healing was verified by the gastroenterologist and upper 
gastrointestinal endoscopy. Patients with treatment success at 4 weeks started 
maintenance treatment with a low-dose PPI and were assumed to remain healed 
for the duration of the model. Patients unhealed at 4 weeks were prescribed a fur-
ther 4-week treatment course with the same high-dose of PPI, followed by a second 
visit with endoscopy was carried out. The analysis was conducted from a public 
payer perspective. Cost of PPIs was derived from the publicly available Ministry of 
Health (MoH) price list. Gastroenterologist visit and endoscopy were estimated on 
the basis of National Health Fund (NHF) data. Data are presented in EUR (1 EUR = 
4.00 PLN). Results: Over the course of 8 weeks, treatment with esomeprazole was 
projected to have slightly better net clinical benefits over treatment with lansopra-
objeCtives: To determine the focus of research on economic burden in gas-
trointestinal disorders from studies published in 2014. Methods: An evidence 
surveillance process was established based on a systematic search of PubMed, 
incorporating all studies published from 2010 and updated weekly, with a final 
search on 1 June 2015. Abstracts identified by the search for costs or resource use 
outcomes in gastrointestinal disorders were identified. Articles were included 
if they reported results from a primary research study, systematic review or 
economic model. Economic outcomes were identified, where possible, from the 
abstract alone. Results: The economic burden search identified 1,870 articles 
published in 2014, with 968 meeting the inclusion criteria for any disease. Of 
these, 88 (9%) were in gastrointestinal disorders, based on ICD-10 classifications. 
Almost half (41 articles) were observational studies, 32 were RCTs or comparative 
studies, 11 were economic evaluations and 4 were literature reviews. Most of the 
studies were relevant to surgical procedures for colorectal surgery (13 articles), 
gall stones or cholecystitis (11), appendicitis (7) or hernia repair (7), with 12 arti-
cles reporting dental procedures. Only eleven articles reported costs or resource 
use associated with medical treatment, mainly for inflammatory bowel disease 
(6 articles) or peptic ulcer (2). The USA was the most common setting, based on 
abstract text or author affiliations (27 articles), followed by the UK (7), Italy and 
China (6 each) and Spain (4). Indirect costs were reported in only 9 articles, of 
which 3 reported productivity losses. No abstract reported caregiver or social care 
costs. Direct costs were evaluated in 60 articles and healthcare resource use in 69 
articles. ConClusions: Recent research on economic burden in gastrointestinal 
disorders has focused disproportionately on direct costs and resource use associ-
ated with surgical procedures. Up-to-date data on indirect costs, and direct costs 
of non-surgical interventions, remains sparse.
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objeCtives: The aim of this study is determine the persistence and economic 
impact of Adalimumab (ADA) discontinuation in inflammatory bowel disease (IBD) 
patients with at least 6 months in Sustained Clinical Remission (SCR). Methods: 
We conducted an observational and retrospective study to assess the persistence 
and economic impact of ADA discontinuation treatment after achieving SCR in IBD 
patients between Jan2009-May 2015. Eligible IBD patients were > 18 years in SCR on 
ADA by maintenance treatment of 40 mg/14days for a minimum of 6 months. We 
collected age, sex, indication, persistence (years) of ADA treatment, ADA discontinu-
ation period (years) and if there was an IBD relapse after the ADA discontinuation. 
We determined the real cost of ADA treatment for each patient from invidualized 
drug dispensations and correlated dates during the study period. The cost sav-
ings obtained during the patients ADA discontinuation was calculated using the 
ADA cost per day for each patient by the days of each patient in complete remis-
sion. Results: From Jan 2009 to May 2015, 18 patients (83% women; age 39±10 
years; 15 Crohn Disease and 3 Ulcerative Colitis) discontinued ADA therapy. These 
patients were on ADA therapy for 2.1±1.2 years towards achieve SCR and stopped 
ADA therapy. The persistence of these patients in SCR (discontinued ADA therapy) 
was 2.3±0.9 years; range 1.1-3.8 years. 6 (33%) patients had an IBD relapsed and 
restarted ADA therapy. During the study period, the total associated ADA costs for 
all IBD patients included was 477.313€ with an ADA patient daily cost of 37.7±12.5€ . 
The implementation of the strategy of ADA discontinuation in IBD patients in SCR 
for at least 6 months produced a cost savings of 520.522,7€ thorough the study 
period. ConClusions: Discontinuation ADA treatment in IBD patients in SCR for 
at least 6 months could make treatment more cost-effective and allow gastroen-
terologists to treat more patients with a fixed budget.
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objeCtives: To map resource use and associated costs of managing chronic hepatitis 
C (CHC) in Greece across all disease stages and discuss simeprevir (SMV) in combina-
tion with pegylated-interferon + ribavirin (PR) as a potential treatment option in the 
early stages. Methods: An expert panel of 8 leading hepatologists determined local 
resource use for CHC. Unit costs were obtained from officially published sources. 
Direct costs (medical, hospital, lab and imaging tests, and pharmaceutical care exclud-
ing anti-viral treatment) were estimated for each of the following health states of the 
disease: non-cirrhotic CHC, compensated cirrhosis, decompensated cirrhosis, hepa-
tocellular carcinoma (HCC) and liver transplantation. Productivity losses were also 
included in the analysis. The perspective was that of the Social Insurance Fund (SIF) 
and the cost base year was 2014. Results: The costs associated with non-cirrhotic 
CHC and compensated cirrhosis were estimated at € 84.65 and € 128.85, respectively, 
consisting mainly of lab and imaging tests. Medical follow up for CHC patients across 
all stages is performed through public hospital outpatient units, without entailing 
costs for SIFs. The annual per patient costs for decompensated cirrhosis, HCC and 
liver transplant were estimated at € 3,170.20, € 8,513.22 and € 129,412, respectively and 
consisted mainly of hospitalization costs. Indirect costs were estimated at € 1,009 for 
both non-cirrhotic and compensated cirrhosis stages, and at € 4,539 for decompen-
sated cirrhosis. ConClusions: Costs of managing CHC increase dramatically with 
disease severity. A recent publication from the UK supports the cost-effectiveness of 
SMV+PR against PR, with an ICER of £9,725/ QALY for treatment-naïve and £7,819/ 
QALY for treatment-experienced patients. Therefore and under the current cost con-
tainment environment in Greece, SMV+PR could be a cost-effective treatment option 
for treating patients earlier to prevent high costs at later stages.
